ImmunityBio Reports Durable Responses in Blood Cancer Study, Plans U.S. Filing for Bladder Cancer by 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- Blood Cancer Study Results: ImmunityBio's QUILT-106 study shows patients achieving complete responses lasting 7 to 15 months post-treatment without further therapy, indicating the therapy's durable efficacy in blood cancer patients, potentially enhancing the company's market share in this segment.
- Bladder Cancer Study Progress: The enrollment for ImmunityBio's bladder cancer study with Anktiva has surpassed 85%, with full enrollment expected by Q2 2026, and plans to submit a biologics license application to the FDA by the end of 2026, showcasing rapid advancements in bladder cancer treatment.
- New Approvals in Saudi Arabia: Saudi regulators have approved Anktiva for bladder cancer patients unresponsive to prior treatments, reinforcing its position in the Middle East and North Africa, while also granting approval for advanced lung cancer patients, demonstrating the drug's broad applicability.
- Positive Market Sentiment: On Stocktwits, retail sentiment for ImmunityBio is extremely bullish, with users expressing optimism that recent regulatory developments could significantly enhance the company's outlook, with sales potentially increasing 3 to 5 times, reflecting strong market confidence in its future performance.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.950
Low
5.00
Averages
7.33
High
9.00
Current: 3.950
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
